NCT07480928 2026-03-18
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2 Recruiting
Clinical Trials
5 trialsNCT04990323 2025-02-25
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
ExCellThera inc.
Phase 1/2 Recruiting
NCT04395092 2021-06-22
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Kiadis Pharma
Phase 2 Withdrawn
NCT01379209 2019-10-23
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
Regimmune Corporation
Phase 1/2 Completed
NCT00189488 2014-09-15
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
Swedish Orphan Biovitrum
Phase 2 Completed